We challenge the notion that influenza B is milder than influenza A by finding similar clinical characteristics between hospitalized adult influenza-cases. Among patients treated with oseltamivir, length of stay and mortality did not differ by type of virus infection.
Infection due to influenza B virus is often perceived to be milder than influenza A virus infection. However, studies have shown similar clinical features between patients infected with seasonal influenza A and B virus in outpatient settings [1, 2] and substantial influenza B infections among pediatric influenza-associated fatalities [3] . In addition, some studies have suggested that oseltamivir may be less effective at reducing fever in outpatients infected with influenza B virus compared with influenza A virus [4] ; very few published studies have compared outcomes among hospitalized patients, especially among adults. We used 8 years of data from adults hospitalized with laboratory-confirmed influenza to compare clinical characteristics between those infected with influenza A and B viruses and to compare outcomes among patients treated with antiviral medications by virus type. In addition, we summarized influenza virus surveillance data from the World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System collaborating laboratories (CDC, unpublished data) for adults (aged ≥21 years) to describe type-specific distribution of influenza viruses circulating during each season included in this analysis.
METHODS
We [5] . Potential confounders such as ICU admission, presence of high-risk medical conditions, and age group were included to produce an adjusted hazard ratio. All statistical analyses were performed using SAS statistical software version 9.3 (Cary, North Carolina). Collection of human subject data has been determined by the CDC to be routine public health surveillance and was not subject to institutional review board approval from human research protections. There were no significant differences between influenza A and B virus infections among hospitalized adults aged ≥65 years regarding presence of high-risk conditions, median length of hospitalization, admission to ICU, or death in the hospital. After adjusting for the presence of high-risk conditions, antiviral treatment, and seasonality, the adjusted odds ratio (aOR) for ICU admission was 1 after adjusting for presence of high-risk conditions, antiviral treatment, and seasonality (aOR, 1.14 [95% CI, . 
RESULTS

We identified 23 186 (87%) influenza
DISCUSSION
The number of hospitalizations associated with influenza A virus infections was greater than the number with influenza B virus infections, reflecting the greater prevalence of influenza A viruses circulating in the community during the seasons in the study period. Our results suggest that the clinical characteristics of hospitalized adults with influenza A and B virus infection, including length of stay, ICU admission, and death during hospitalization were comparable. Other studies have reported similar clinical characteristics between outpatients [2] and hospitalized children [1, 6, 7] with influenza A and B virus infections prior to the 2009 pandemic. However, some studies suggest that during seasons when A(H3N2) was the predominant subtype, outpatients with influenza A virus infection reportedly sought care earlier than patients with influenza B virus infection [2] , and influenzaassociated mortality estimates are reported to be the highest during A(H3N2)-predominant seasons [8] . We did not have subtype information available for most patients, limiting our ability to stratify the analysis by influenza A virus subtype. However, during most A(H3N2)-predominant seasons, we did not find a greater proportion of ICU admission among patients with influenza A compared with B virus infections. We only found a higher proportion of ICU admission among patients aged 18-64 years with influenza A virus infection during the 2010-2011 season, when A(H3N2) viruses predominated. However, there was co-circulation of A(H1N1)pdm09 virus, and patients infected with the A(H1N1)pdm09 virus strain were reported to have more severe outcomes than patients with A (H3N2) virus infection [9] . No increased severity in patients with influenza A was observed during the pandemic, which was likely due to the rare circulation of influenza B viruses during that period. Thus, our findings suggest that influenza B virus infections caused substantial morbidity among hospitalized adults and should not be regarded as a less severe infection than influenza A virus infection when considering treatment options.
Influenza B viruses have a higher baseline 50% inhibitory concentration (IC 50 ) value for oseltamivir than influenza A viruses in in vitro neuraminidase inhibition assays [10] . Some investigators have questioned whether this difference is associated with altered drug effectiveness. Also, observational studies have suggested that oseltamivir treatment may reduce fever more quickly with influenza A compared with influenza B virus infections [4] . Although we were not able to explore all clinical outcome differences, such as duration of fever or virus shedding, we found no differences in length of hospital stay and mortality that have been reported in observational studies of antiviral effectiveness among hospitalized patients [11, 12] .
This study has limitations. The FluSurv-Net surveillance relies on clinicians ordering influenza testing. We do not know if testing practice has changed over time or whether physicians were more likely to test more severe hospitalized cases. Nonetheless, none of these limitations are likely to affect our results, as physicians cannot distinguish influenza type by signs and symptoms at presentation when ordering testing.
In conclusion, among hospitalized adults, influenza A and B infections resulted in similar morbidity and mortality. Antiviral treatment should be recommended for all hospitalized patients with suspected or confirmed influenza virus infection. Our results indicate that the type of influenza virus infection should not influence treatment decisions.
Notes
